9:34 AM
Jan 09, 2019
 |  BC Innovations  |  Distillery Therapeutics



Mouse studies suggest inhibiting SGLT2 could help treat G6PC3 deficiency-induced neutropenia. In a mouse model of G6PC3 deficiency, the SGLT2 inhibitor Jardiance empagliflozin decreased granulocyte maturation arrest in the bone marrow and increased the numbers of circulating...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >